The role of α2‐adrenoceptor antagonism in the anti‐cataleptic properties of the atypical neuroleptic agent, clozapine, in the rat
- 1 August 1998
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 124 (7) , 1550-1556
- https://doi.org/10.1038/sj.bjp.0701975
Abstract
1. The mechanism underlying the anticataleptic properties of the atypical neuroleptic agent, clozapine, has been investigated in the rat. 2.The close structural analogues of clozapine, loxapine (0.1 mg kg(-1) s.c.) and iso-clozapine (1 and 3 mg kg(-1) s.c.) induced catalepsy in rats. In contrast, clozapine and the regio-isomer of loxapine, iso-loxapine (up to 10 mg kg(-1) s.c.) did not produce catalepsy, but at a dose of 1 mg kg(-1) significantly inhibited catalepsy induced by loxapine (0.3 mg kg(-1) s.c.). 3. Radioligand binding assays showed that cataleptogenic potential was most clearly predicted by the D2/5-HT1A, D2/5-HT1B/1D and D2/alpha2-receptor affinity (KD) ratios: i.e. 30-100-fold higher ratios were calculated for loxapine and iso-clozapine, whereas the ratios were less than 1 for clozapine and iso-loxapine. The ratios of affinities for D2 to 5-HT2A, 5-HT2C or D1 did not reflect the grouping of cataleptic and non-cataleptic compounds. 4. Co-treatment with the alpha2-adrenoceptor antagonists, yohimbine (1-10 mg kg(-1) s.c.), RX 821002 (1-10 mg kg(-1) s.c.) and MK-912 (0.3 and 1 mg kg(-1) s.c.) dose-dependently inhibited the cataleptic response to loxapine (0.3 mg kg(-1)). Yohimbine (1-10 mg kg(-1) s.c.) also dose-dependently inhibited the cateleptic response to haloperidol (0.3 mg kg(-1) s.c.). The alpha2-adrenoceptor antagonists had no effect per se. 5. Neither yohimbine (10 mg kg(-1)) nor RX821002 (3 mg kg(-1)) altered the cataleptic response to the D1 receptor antagonist, SCH 23390 (1 mg kg(-1) s.c.), while, like clozapine, both compounds abolished the response to the 5-HT2A receptor antagonist, MDL 100,151 (3 mg kg(-1) s.c.). 6. The present data strongly implicate alpha2-adrenoceptor blockade in the anticataleptic properties of clozapine and suggest that its lack of extrapyramidal side effects in the clinic may also be a consequence of this property.Keywords
This publication has 36 references indexed in Scilit:
- Modification of reserpine induced rigidity by dopaminergic and alpha-adrenergic drugsActa Neurologica Scandinavica, 2009
- The emergin role of clozapine in the treatment of movement disordersMovement Disorders, 1997
- Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptorsNeuropsychopharmacology, 1997
- 5-HT1A receptors are not involved in clozapine's lack of cataleptogenic potentialNeuropharmacology, 1996
- SDZ PSD 958, a novel D1 receptor antagonist with potential limbic selectivityJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1996
- Startle and sensorimotor correlates of ventral thalamic dopamine and GABA in rodentsNeuroReport, 1995
- Charting the circuitsNature, 1995
- Putting the 'A' in atypical: does α2-adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics?Journal of Psychopharmacology, 1994
- Effect of Nondopaminergic Drugs on L-DOPA-Induced Dyskinesias in MPTP-Treated MonkeysClinical Neuropharmacology, 1993
- Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH 23390 in the ratJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1992